| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
This study used radiolabeled components to determine the dermal absorption of camphene, isoborneol acetate, limonene, menthol, and α-pinene from a pinimenthol bath in animals. Pharmacokinetic measurements showed that all test components reached peak plasma concentrations 10 minutes after the onset of dermal absorption. No preferential absorption was observed for any component. Ten minutes after dermal absorption, plasma concentrations of all components were positively correlated with skin contact area. Metabolism/Metabolites Isoborneol acetate is rapidly hydrolyzed (within hours) in the first step of its biochemical pathway to produce isoborneol. This alcohol will bind to glucuronic acid and be excreted in the urine (expected within hours to days). |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
Identification and Uses: Isoborneol acetate is used in soaps, detergents, creams, lotions, and perfumes. Human Studies: Maximum dose tests were conducted on 25 volunteers. No sensitization was observed when the substance was tested at a 10% concentration. Animal Studies: Mild irritation was observed when undiluted isoborneol acetate was applied to intact or abraded rabbit skin and left closed for 24 hours. Rats were administered isoborneol acetate daily at doses of 0, 15, 90, or 270 mg/kg body weight for 13 weeks. Male rats showed nephrotoxicity at doses of 90 mg/kg and 270 mg/kg/day, and hepatotoxicity at a dose of 270 mg/kg. In single-generation breeding studies in rats, isoborneol acetate did not exhibit developmental toxicity. Throughout the administration period, both male and female parental rats in the 100 and/or 300 mg/kg/day dose groups showed an increased incidence of excessive salivation, while female rats in the gestational 300 mg/kg/day dose group had a lower incidence of small amounts of urine staining their abdominal fur. Non-human toxicity values Rabbit dermal LD50 >20 g/kg Rats oral LD50 >10 g/kg Mice oral LD50 3100 mg/kg Rats oral LD50 9050 mg/kg |
| References | |
| Additional Infomation |
It has been reported that artemisia, turmeric, and other organisms with relevant data contain borneol acetate.
Mechanism of Action One possible explanation for the nephrotoxicity observed in males rather than females is the accumulation of α-2u-globulin, a protein that appears to contribute to the formation of renal tubular tumors in the kidneys of male rats. |
| Molecular Formula |
C12H20O2
|
|---|---|
| Molecular Weight |
196.29
|
| Exact Mass |
196.146
|
| CAS # |
125-12-2
|
| Related CAS # |
Bornyl acetate;76-49-3
|
| PubChem CID |
6448
|
| Appearance |
Colorless to very pale straw-colored liquid
|
| Density |
0.983 g/mL at 25 °C(lit.)
|
| Boiling Point |
229-233 °C(lit.)
|
| Melting Point |
29°C
|
| Flash Point |
190 °F
|
| Vapour Pressure |
0.0959mmHg at 25°C
|
| Index of Refraction |
n20/D 1.4635(lit.)
|
| LogP |
2.764
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
270
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)O[C@H]1C[C@@H]2CC[C@@]1(C)C2(C)C
|
| InChi Key |
KGEKLUUHTZCSIP-JBLDHEPKSA-N
|
| InChi Code |
InChI=1S/C12H20O2/c1-8(13)14-10-7-9-5-6-12(10,4)11(9,2)3/h9-10H,5-7H2,1-4H3/t9-,10-,12+/m0/s1
|
| Chemical Name |
[(1S,2S,4S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0945 mL | 25.4725 mL | 50.9450 mL | |
| 5 mM | 1.0189 mL | 5.0945 mL | 10.1890 mL | |
| 10 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
